WHAT IS CLAIMED:

1. ~~A~~ Use of a pharmaceutical composition comprising a diketopiperazine with amino acid side chains of aspartic acid and alanine (DA-DKP) in the manufacture of a medicament for the treatment ~~for use in the treatment~~ of rhinitis.
2. The use as claimed in claim 1, wherein the rhinitis is allergic rhinitis.
3. The use as claimed in claim 1, wherein the effective amount of the DA-DKP in the composition is from 100 µg to 3000 µg per day.
4. The use as claimed in claim 1, wherein the effective amount of the DA-DKP in the composition is from about from 500 µg to 1500 µg per day.
5. The use as claimed in claim 1, wherein administration of the composition comprising DA-DKP, is commenced within 24 hours of diagnosis of rhinitis.
6. The use as claimed in claim 1, wherein administration of the composition comprising DA-DKP, is commenced at the appearance of one or more early signs of, or a predisposition to develop, rhinitis.
7. The use as claimed in claim 6, wherein the one or more early signs of rhinitis are selected from the group consisting of rhinorrhea, nasal congestion, nasal itching and sneezing.
8. The use as claimed in claim 1, wherein the DA-DKP is in a composition prepared by removing albumin from a solution of a human serum albumin composition.
9. The use as claimed in claim 8, wherein the step of removing the albumin comprises treating the human serum albumin composition by a separation method selected from the group consisting of ultrafiltration, sucrose gradient centrifugation, chromatography, salt precipitation, and sonication.
10. The use as claimed in claim 9, wherein the step of removing comprises passing the human serum albumin composition over an ultrafiltration membrane with a molecular weight cut off that retains the albumin, and wherein the resulting filtrate comprises DA-DKP.
11. The use as claimed in claim 10, wherein the ultrafiltration membrane has molecular weight cutoff of less than 50 kDa, less than 40 kDa, less than 30 kDA, less than 20 kDa, less than 10 kDa, less than 5 kDa or less than 3 kDA.
12. The use as claimed in claim 1, wherein the composition comprising DA-DKP is administered in combination with a second drug suitable for treating rhinitis.